Form 4: Wallace L Hall Jr. Acquires Stock Options in Tvardi Therapeutics
SEC Form 4 Filing
Director Wallace L Hall Jr. acquired 12,000 stock options in Tvardi Therapeutics on April 17, 2025, according to a Form 4 filing.
Summary
- Wallace L Hall Jr., a director of Tvardi Therapeutics, acquired 12,000 stock options on April 17, 2025.
- The exercise price of these options is $17.04.
- The options vest in 12 equal quarterly installments over three years, starting July 17, 2025, contingent upon continuous service.
- The options expire on April 16, 2035.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock option grants, which is neutral in sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This provides transparency to the market.
Stakeholder Impact
- The acquisition of stock options by a director could be seen positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 04/17/2025 | Date of transaction: Wallace L Hall Jr. acquired 12,000 stock options. |
| 07/17/2025 | Vesting start date: Options vest in 12 equal quarterly installments commencing on this date. |
| 04/16/2035 | Expiration date: Options expire on this date. |
| 04/21/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Tvardi Therapeutics, Stock Options, Beneficial Ownership, Director, TVRD, Hall, Wallace
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.